Brooklyn Investment Group Grows Stake in Danaher Co. (NYSE:DHR)

Brooklyn Investment Group grew its holdings in Danaher Co. (NYSE:DHR) by 7.7% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 5,289 shares of the conglomerate’s stock after buying an additional 378 shares during the quarter. Brooklyn Investment Group’s holdings in Danaher were worth $1,214,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the business. FMR LLC lifted its holdings in Danaher by 15.8% in the 3rd quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after buying an additional 3,217,631 shares during the period. Legal & General Group Plc raised its position in shares of Danaher by 2.4% in the 2nd quarter. Legal & General Group Plc now owns 5,964,031 shares of the conglomerate’s stock worth $1,490,112,000 after acquiring an additional 139,989 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Danaher by 3.0% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,097,986 shares of the conglomerate’s stock worth $1,417,342,000 after acquiring an additional 148,251 shares in the last quarter. Fisher Asset Management LLC raised its position in shares of Danaher by 2.6% in the 3rd quarter. Fisher Asset Management LLC now owns 4,552,640 shares of the conglomerate’s stock worth $1,265,725,000 after acquiring an additional 116,299 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA raised its position in shares of Danaher by 17.6% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock worth $996,141,000 after acquiring an additional 535,254 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

Shares of DHR opened at $238.41 on Friday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. Danaher Co. has a one year low of $222.53 and a one year high of $281.70. The firm has a market capitalization of $172.20 billion, a P/E ratio of 45.50, a PEG ratio of 4.23 and a beta of 0.83. The business has a fifty day moving average of $234.99 and a 200 day moving average of $253.37.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The company had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same quarter in the previous year, the company posted $2.02 earnings per share. Danaher’s revenue was up 3.1% compared to the same quarter last year. As a group, sell-side analysts anticipate that Danaher Co. will post 7.49 EPS for the current year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be issued a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.45%. The ex-dividend date is Friday, December 27th. Danaher’s dividend payout ratio is presently 20.61%.

Analyst Ratings Changes

DHR has been the subject of several research reports. Wolfe Research raised Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 target price for the company in a research report on Thursday, October 31st. Guggenheim started coverage on Danaher in a research report on Thursday, December 19th. They issued a “buy” rating and a $275.00 target price for the company. Scotiabank started coverage on Danaher in a research report on Monday, December 23rd. They set a “sector perform” rating and a $265.00 price objective for the company. UBS Group reduced their price objective on Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research report on Wednesday, October 23rd. Finally, TD Cowen raised their price objective on Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research report on Wednesday, October 23rd. Six research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $286.80.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.